Has Joseph Chao received payments from drug or device companies?

Yes. Drug and device makers reported $109,641 in general payments to Joseph Chao across 83 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Joseph Chao did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Joseph Chao come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Joseph Chao

Medical Oncology · Duarte, CANPI 1285831057

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $69,042 of the $109,641 with a category attached, or 63.0%. 15 manufacturers reported payments, led by Merck at 40.1% of the total. Reporting peaked in 2021 at $30,013 and has fallen 99.9% since, to $31 in 2025.

$109,641in general payments, 2019–2025

Across 83 payments — averaging $1320.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$44K
E.r. Squibb & Sons, L.L.C.$22K
Lilly USA, LLC$12K
F. Hoffmann-la Roche AG$8K
Daiichi Sankyo Inc.$8K
Amgen$6K
plus $9K from 9 others

$3,861,979in research payments, 2019–2025

Across 194 payments — averaging $19,907 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$1M
Amgen$775K
E.r. Squibb & Sons, L.L.C.$753K
Seagen Inc.$412K
Daiichi Sankyo Inc.$341K
Sanofi US Services Inc.$279K
plus $278K from 2 others

What the payments were for

Consulting fees$69,04263%
Speaking & faculty fees$35,78533%
Travel & lodging$3,3563%
Food & beverage$1,4581%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	28	$43,929
E.r. Squibb & Sons, L.L.C.	15	$22,050
Lilly USA, LLC	7	$11,918
F. Hoffmann-la Roche AG	3	$8,415
Daiichi Sankyo Inc.	14	$7,988
Amgen	4	$6,446
Astrazeneca UK Limited	1	$2,398
Foundation Medicine, Inc.	3	$1,829
Taiho Oncology, Inc.	1	$1,800
Novartis	1	$1,638
Coherus Oncology, Inc.	1	$900
Dova Pharmaceuticals	1	$150
Biocryst US Sales Co., LLC	1	$98
AbbVie	2	$59
Array Biopharma Inc	1	$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$109,641 in reported general payments places this provider in the 85th percentile of 379 medical oncology providers in California.

See all medical oncology providers in California →

Other medical oncology in Duarte

Daneng LiDuarte$467K
Howard WestDuarte$426K
Christine LovlyDuarte$362K
Marwan FakihDuarte$203K
Erminia MassarelliDuarte$176K
Ravi SalgiaDuarte$142K
Tanya DorffDuarte$136K
Karen ReckampDuarte$132K
Cy SteinDuarte$122K
Stephen SherwinSan Francisco$6.9M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →